Ah Changes Are Taking The Pace I'm Going Through
Entry 1 11:24 a.m.
Big news on the work front. Jenny has decided it makes sense to go on long-term disability, rather than working. This pleases me. She came home half-dead this week, as she went to TOPs to help with buses and lunches. We will be fine with her being on LTD, and it will allow her to continue to volunteer to do things she loves, to see friends, to travel. Her friend that bought her the handmade mattress is going to fly up and get Jenny in her private jet and take her to San Francisco for a few days, something that would not have been possible if she had opted to work.
Truth is, she realizes that as much as she would like to work, it is just too much. It just is. I am glad she has made this decision. It took a long time to get her used to the idea, but she is there, and I am relieved.
More on Cancerembryonic Antigen (CEA)
Jenny's CEA is at 14.3 ng/ml, for reference. She is making all this research fall apart, as she beats all expectations:
Results: Median overall survival (OS) was significantly shorter for patients with high CEA (>5 ng/ml) than with normal CEA (≤5 ng/ml) (6.8 vs. 10.3 months, respectively; p < 0.001). After adjustment, CEA level was an independent predictive factor for OS (hazard ratio [HR], 1.81; 95% confidence interval [CI], 1.45-2.26). In the high CEA group, OS in patients treated with combination chemotherapy was similar to that with single-agent chemotherapy (median, 7.1 vs. 6.8 months; HR for OS, 0.99; 95% CI, 0.71-1.40).
Conclusions: The present results show that CEA level is an independent prognostic factor in patients with metastatic PC. A combination chemotherapy regimen may offer modest survival benefit in patients with high CEA.
One of the key reasons that Jenny is alive, besides sheer will and tenacity, I believe, may be the Chinese medicine regimen she follows daily. Have I mentioned this? Here is the summary from an excellent summary of it's efficacy, when used in combination with chemotherapy:
Pancreatic cancer has the lowest survival rate among all cancers. The mean survival is 14 months after resection and 5 months after palliative surgery. For patients with metastatic pancreatic cancer, standard chemotherapy treatment yields a median survival of only 6 months. The National Cancer Institute’s SEER survival monograph showed that the 5-year survival rate for 20,829 pancreatic adenocarcinoma patients was only 2.3%.
-- -- -- -- -- --
The survival of patients who received CHM ranged from 4 months to 10 years, with a mean 29.6 months and median 15.2 months. Seventy-six percent survived at least 1 year. The results support a better prognosis for pancreatic cancer patients who receive CHM treatment compared with conventional treatment alone.
My knee keeps locking. It is painful, quite so, but more annoying than anything. Gravity always wins.
Comments
Post a Comment